{"name":"HOSPIRA","slug":"hospira","ticker":"","exchange":"","domain":"hospira.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1991-01-01","label":"Nipent first approved","drug":"Nipent","drugSlug":"pentostatin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Epoetin biosimilar","genericName":"Epoetin biosimilar","slug":"epoetin-biosimilar","indication":"Anemia associated with chronic kidney disease","status":"phase_2"},{"name":"Silapo","genericName":"EPOETIN ZETA","slug":"epoetin-zeta","indication":"Anemia in chronic kidney disease","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"FLOX","genericName":"FLOX","slug":"flox","indication":"Malignant neoplasm of liver","status":"marketed"},{"name":"Nipent","genericName":"PENTOSTATIN","slug":"pentostatin","indication":"Hairy cell leukemia","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"DA-9501","genericName":"DA-9501","slug":"da-9501","indication":"Chronic liver disease / Hepatic fibrosis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Dexmedetomidine, midazolam; fentanyl","genericName":"Dexmedetomidine, midazolam; fentanyl","slug":"dexmedetomidine-midazolam-fentanyl","indication":"Sedation in intensive care unit (ICU) patients","status":"phase_2"}]}],"pipeline":[{"name":"Epoetin biosimilar","genericName":"Epoetin biosimilar","slug":"epoetin-biosimilar","phase":"phase_2","mechanism":"Stimulates erythropoiesis by binding to the erythropoietin receptor","indications":["Anemia associated with chronic kidney disease","Anemia associated with chemotherapy"],"catalyst":""},{"name":"FLOX","genericName":"FLOX","slug":"flox","phase":"marketed","mechanism":"Thymidylate synthase, Thymidylate synthase","indications":["Malignant neoplasm of liver","Primary malignant neoplasm of gastrointestinal tract"],"catalyst":""},{"name":"DA-9501","genericName":"DA-9501","slug":"da-9501","phase":"phase_3","mechanism":"DA-9501 is a standardized herbal extract that modulates inflammatory and immune pathways to improve hepatic function and reduce liver injury.","indications":["Chronic liver disease / Hepatic fibrosis","Drug-induced liver injury"],"catalyst":""},{"name":"Dexmedetomidine, midazolam; fentanyl","genericName":"Dexmedetomidine, midazolam; fentanyl","slug":"dexmedetomidine-midazolam-fentanyl","phase":"phase_2","mechanism":"Alpha-2 adrenergic receptor agonist","indications":["Sedation in intensive care unit (ICU) patients","Anesthesia"],"catalyst":""},{"name":"Nipent","genericName":"PENTOSTATIN","slug":"pentostatin","phase":"marketed","mechanism":"Adenosine deaminase","indications":["Hairy cell leukemia"],"catalyst":""},{"name":"Silapo","genericName":"EPOETIN ZETA","slug":"epoetin-zeta","phase":"marketed","mechanism":"Erythropoietin receptor","indications":["Anemia in chronic kidney disease"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":2,"marketed":3,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}